(Reuters) -The World Health Organization (WHO) said on Tuesday that drug resistance is growing in HIV patients who received GSK’s treatment, dolutegravir.
The resistance is exceeding levels observed in clinical trials, the global health agency said, citing observational and country-generated survey data.
It ranged from 3.9% to 8.6% and reached 19.6% among people who received the treatment and transitioned to a dolutegravir-containing antiretroviral therapy while having high HIV viral loads.
GSK did not immediately respond to a Reuters request for comment.
Since 2018, the WHO has recommended the use of dolutegravir as the preferred first- and second-line HIV treatment for all population groups.
(Reporting by Sriparna Roy in Bengaluru; Editing by Arun Koyyur)
Disclaimer: This report is auto generated from the Reuters news service. ThePrint holds no responsibilty for its content.